Objectives: To evaluate if there are significant drug-drug interactions between cobicistat-boosted elvitegravir and 800 mg darunavir once daily taken simultaneously, as has been suggested previously.
Introduction
Suboptimal adherence to ART often results in persistent viral replication, the emergence of resistance mutations and a loss of therapeutic options. Currently, there are several fixed-dose combinations of antiretroviral drugs co-formulated as a single tablet to be taken once daily. These combinations facilitate treatment adherence, but their use is limited to patients without resistance to any of the components.
In contrast, a higher pill burden and sometimes twice-a-day dosages are often required to attain a completely active regimen for treatment-experienced patients exhibiting drug resistance. This is especially troublesome for patients with a particular aversion to taking pills, for whom treatment dropouts and resistance-associated mutations are more the rule than the exception, especially for patients with a long treatment history. 1, 2 There is a close relationship between adherence, pill number and daily dosing frequency. [3] [4] [5] Thus, the prospect of administering a regimen containing two or three potent and fully active drugs in only two pills taken once daily make the combination of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, coformulated in a single tablet, plus 800 mg darunavir once daily, of particular interest for patients with the characteristics mentioned above. However, the pharmacokinetic data about this combination are scarce and contradictory. One retrospective case series with this combination found mean estimated darunavir trough concentrations that were 80% lower than the historical population mean in subjects reporting 100% adherence. 6 If so, this drug-drug interaction would compromise the effectiveness of the combination and facilitate the emergence of new resistant mutations. In this study, we analysed elvitegravir, cobicistat and darunavir concentrations at the end of a dosing interval (C 24 ) in patients taking co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate plus 800 mg darunavir simultaneously. We compared the results with the concentrations observed in subjects taking either co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate or cobicistat-boosted darunavir (800 mg darunavir þ 150 mg cobicistat) once daily. 
Methods

Study population
The enrolled patients were treated at the Infectious Diseases Department of the Virgen del Rocio University Hospital (Seville, Spain). The study population consisted of three groups of unselected volunteer patients. Group A comprised patients on a regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate (150/150/200/300 mg) co-formulated in a single tablet together with 800 mg darunavir once daily as a salvage regimen. The patients were naive to integrase inhibitors and had no major HIV resistance mutations to boosted darunavir according to the 2014 International AIDS Society. 7 An estimated glomerular filtration rate of at least 70 mL/min was required. Group B consisted of patients taking only coformulated elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, and group C consisted of patients on cobicistat-boosted darunavir (800 mg darunavir þ 150 mg cobicistat) once daily plus two nucleos(t)ide analogues. These regimens were not prescribed in cases of pregnancy or concomitant use of drugs with potential interactions with any of the components of these regimens.
8,9
Ethics
The study was approved by the Ethics Committee of the Virgen del Rocio University Hospital. All of the patients provided informed consent.
Blood sampling and drug concentration determinations
Blood samples were obtained at least one month after starting the treatments. The patients were instructed to take their drugs in the morning after a standard breakfast and to record the time that they had taken the medication on the previous day. Samples were obtained 24 h (615 min) after the previous dose (blood samples were not taken otherwise) and processed within 1 h. Elvitegravir, cobicistat and darunavir C 24 were quantified using a validated LC-MS method. Separation was performed on a Phenomenex Luna C18 analytical column (5 lm, 150 mm Â 2.0 mm). The mobile phase was composed of 2 mM ammonium acetate with 0.1% formic acid (solvent A) and acetonitrile 0.1% formic acid (solvent B). The drugs were extracted from the plasma by protein precipitation using acetonitrile containing a deuterated internal standard. The standard curves were highly linear over the ranges of 25-2500 ng/mL, 2-2000 ng/mL and 50-10 000 ng/mL for elvitegravir, cobicistat and darunavir, respectively. The intra-and interassay precision and accuracy were <15%.
Statistical analysis
Elvitegravir, cobicistat and darunavir C 24 were summarized using geometric means (GMs), IQRs and ranges. The drug concentrations were compared between the different groups using the Mann-Whitney test and ANOVA. The Pearson's v 2 test or Fisher's exact test was used to compare categorical variables. Both the intra-and inter-subject variability in drug concentrations was measured using the coefficients of variation (CV) of the available values from each subject. A P value 0.05 was considered to be statistically significant.
Results
The participants included 88 patients: 24 in group A (44 samples), 32 in group B (91 samples) and 32 in group C (35 samples). Their baseline characteristics are listed in Table 1 . Figure 1 shows the C 24 concentrations for the three groups. In group A, 20 out of the 24 patients (83.3%) had an undetectable viral load at week 24.
The elvitegravir C 24 concentrations in group A (233.67 ng/mL; range 91.78-431.59) were only 6.6% lower than those in group B (250.39 ng/mL; range 30.35-762.34) (P ¼ 0.406), as shown in Figure 1(a) . Likewise, the darunavir C 24 concentrations in group A (1293.54 ng/mL; range 162.51-3640.86) were almost the same as that in reference group C (1319.34 ng/mL; range 288.14-3640.86) (P ¼ 0.908), as shown in Figure 1(b) . The cobicistat C 24 concentrations in groups A and B were comparable (20.2 versus 20.9 ng/mL) (P ¼ 0.132), but slightly lower than that in group C (27.7 ng/mL) (P ¼ 0.059), as shown in Figure 1(c) .
The median intra-patient variabilities were 36.8% (range 2.3-112.8) for elvitegravir and 39.8% (range 15.9-129.7) for cobicistat in the 22 patients with repeated samples in groups A and B. For darunavir, there were only three patients with repeated samples. The median inter-patient variabilities were 58.4%, 76.6% and 64.7% for elvitegravir, cobicistat and darunavir, respectively.
Discussion
The full prescribing information for co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate advises against using it in conjunction with PIs due to potential drug-drug interactions, including altered or suboptimal pharmacokinetics of cobicistat, elvitegravir or the co-administered antiretrovirals. Interactions between cobicistat-boosted elvitegravir and darunavir JAC Furthermore, since co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate is considered a complete regimen for the treatment of HIV-1 infection, no information is provided about drug interactions with other antiretrovirals. 8 Therefore, there is insufficient evidence to ensure the absence of pharmacokinetic interactions for the combination of co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate plus 800 mg darunavir once a day.
Our results revealed no differences in the plasma C 24 concentrations of elvitegravir and darunavir when co-administered and boosted with 150 mg cobicistat in the single tablet of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate or when elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate and cobicistat-boosted darunavir were dosed separately. Regarding the darunavir C 24 concentrations, we previously reported a GM darunavir C 24 concentration of 1820 ng/mL (IQR 1470-2460) in 587 samples from 119 subjects taking ritonavirboosted darunavir (100/800 mg once a day) drawn under the same conditions described above. 10 Thus, the C 24 concentrations of darunavir were 30% lower when boosted with cobicistat relative to ritonavir. These results are similar to those reported by Kakuda et al.
11 in a pharmacokinetic study performed in healthy volunteers, which compared ritonavir-boosted darunavir with darunavir in a fixed-dose combination with cobicistat. Likewise, no significant differences were observed in the plasma concentrations of elvitegravir and darunavir when dosed as elvitegravir plus ritonavir (125/100 mg once daily) and ritonavir-boosted darunavir (600/ 100 mg twice daily) compared with the co-administration of elvitegravir (125 mg) plus darunavir (600/100 mg twice daily). 12 In a more recent study, the plasma concentrations of elvitegravir and darunavir fell into the therapeutic range in 15 patients who switched to elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide plus 800 mg of darunavir given as a once-daily regimen, although no drug-drug interactions were studied. 13 It is for these reasons that the study by Ricard et al., 6 which reported estimated mean darunavir trough concentrations in 23 samples from eight Figure 1 . GM of elvitegravir, darunavir and cobicistat plasma C 24 when these drugs were co-administered or dosed separately. ELV, elvitegravir; DRV, darunavir; cobi, cobicistat; E/C/F/TDF, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
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subjects that were 80% lower than the historical population values, raises concerns about this combination. However, the main limitation of this study was that the reported trough concentrations were estimated from different determinations during the dosing interval using a theoretical elimination half-life of darunavir of 7.5 h, which could lead to significant errors. On the other hand, the difference in cobicistat C 24 concentrations between the patients taking elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate and those on cobicistat-boosted darunavir (group C) was small and likely of no clinical significance. Our study has several limitations, however: for example, the patients were not randomized and we only measured C 24 concentrations. Thus, the complete absence of drug-drug interactions with the combination of co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate or tenofovir alafenamide with 800 mg darunavir would have to be demonstrated in a future trial assessing different pharmacokinetic parameters. However, the present results provide evidence of similar elvitegravir and darunavir C 24 concentrations when these drugs are co-administered or dosed separately.
